AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10888287 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins
Number of subjects: 24
Study 9387530 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg q.12.h. for 2 days
Number of subjects: 124
Study 9387530 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed for 2 days before labor induction by PG05 or oxytocin)
Number of subjects: 124
Study 1492226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP16‐213)
Number of subjects: 0
Study 1492226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide in combination with amsacrine
Number of subjects: 0
Study 1492226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide in combination with 5‐azacytidine
Number of subjects: 0
Study 1492226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide in combination with anthracycline
Number of subjects: 0
Study 1492226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0
Study 3800342 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 120
Study 3800342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31556667 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (pain management course)
Number of subjects: 471
Study 31556667 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 471
Study 30001744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 121
Study 30001744 — intervention group
Group type: COMPARATOR
Intervention: Fipronil/(S)-methoprene (Frontline Combo® Spot-on Cats)
Number of subjects: 121
Study 27075027 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief multimodal psychosomatic therapy (BMPT) combined with usual care (UC)
Number of subjects: 42
Study 27075027 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 42
Study 24582273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Framingham Coronary Risk Score (FCRS) of 20% or more
Number of subjects: 4731
Study 24582273 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk prediction model
Number of subjects: 4731
Study 24582273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FCRS of 20% or more
Number of subjects: 4731
Study 22170375 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-P-LGI diet
Number of subjects: 13
Study 22170375 — intervention group
Group type: COMPARATOR
Intervention: LC-CONV diet
Number of subjects: 13
Study 22170375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study 19930140 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP3 completion among children who were <=60 days old at enrollment
Number of subjects: 378
Study 19930140 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP3 completion among children living in households with monthly income >Rs. 3000 (US$ 50)
Number of subjects: 378
Study 19930140 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP3 completion among children living <=10 min away from EPI centre
Number of subjects: 378
Study 17402946 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees lateral position
Number of subjects: 55
Study 17402946 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 55
Study 16230563 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin A
Number of subjects: 43
Study 16230563 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U of botulinum toxin A
Number of subjects: 43
Study 16230563 — intervention group
Group type: COMPARATOR
Intervention: Both doses (100 U and 200 U)
Number of subjects: 43
Study 12119475 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (12.5 mg.kg(‐1).min(‐1))
Number of subjects: 2
Study 12119475 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (0.0125 mg.kg(‐1).min(‐1))
Number of subjects: 2
Study 11233190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (Ventak AV II DR)
Number of subjects: 52
Study 7797033 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 mg/kg
Number of subjects: 12
Study 7797033 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 3.0 mg/kg
Number of subjects: 12
Study 7797033 — intervention group
Group type: COMPARATOR
Intervention: Atropine 6 micrograms.kg-1.h-1 for 30 minutes
Number of subjects: 12
Study 7797033 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 2179277 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine 20 mg tid
Number of subjects: 18
Study 2179277 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 161758 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase treated allogeneic myeloblasts
Number of subjects: 0
Study 161758 — intervention group
Group type: COMPARATOR
Intervention: Neuraminidase treated myeloblasts plus MER
Number of subjects: 0
Study 161758 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 31720722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise therapy (7 sessions over 12 weeks)
Number of subjects: 615
Study 31720722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (7 sessions over 12 weeks)
Number of subjects: 615
Study 31720722 — intervention group
Group type: COMPARATOR
Intervention: Single session of physiotherapy education (SSPT)
Number of subjects: 615
Study 31121087 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16
Study 28461207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg every 12 h for 10 days)
Number of subjects: 100
Study 28461207 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg every 6 h for 10 days)
Number of subjects: 100
Study 28461207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 100
Study 28461207 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study 25833230 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 57
Study 25833230 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 57
Study 24290848 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-supported training (MST) for the chronic stroke patient
Number of subjects: 1
Study 24290848 — intervention group
Group type: COMPARATOR
Intervention: Music training for healthy older adults
Number of subjects: 1
Study 22282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine 0.5% drops (Group 1)
Number of subjects: 120
Study 22282296 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine + 4% lidocaine-soaked cotton tipped swabs (Group 2)
Number of subjects: 120
Study 22282296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% lidocaine gel (Group 3)
Number of subjects: 120
Study 20817301 — intervention group
Group type: EXPERIMENTAL
Intervention: ABRI-1 (number of blood units/(final‐initial hematocrit+0.01))
Number of subjects: 242
Study 20817301 — intervention group
Group type: EXPERIMENTAL
Intervention: ABRI-2 (number of blood units/(final‐initial hematocrit+0.01))
Number of subjects: 242
Study 20817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno IV criteria without ABRI
Number of subjects: 242
Study 20817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno IV criteria with ABRI-1
Number of subjects: 242
Study 20817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno IV criteria with ABRI-2
Number of subjects: 242
Study 17197406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 100
Study 17197406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15164895 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 32
Study 15164895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11895066 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 0
Study 9534831 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT x 3 (three times weekly)
Number of subjects: 0
Study 9534831 — intervention group
Group type: COMPARATOR
Intervention: ECT x 2 (twice weekly)
Number of subjects: 0
Study 7631519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei GG (LGG)
Number of subjects: 54
Study 7631519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2716439 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg tenilsetam
Number of subjects: 15
Study 2716439 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenilsetam
Number of subjects: 15
Study 2716439 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg tenilsetam
Number of subjects: 15
Study 2716439 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg co-dergocrine-mesylate
Number of subjects: 15
Study 2716439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2716439 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor measures
Number of subjects: 15
Study 7023894 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg naltrexone administered thrice weekly
Number of subjects: 119
Study 7023894 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg naltrexone administered thrice weekly
Number of subjects: 119
Study 30375144 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 (40-70 J)
Number of subjects: 20
Study 30375144 — intervention group
Group type: COMPARATOR
Intervention: Topical PUVA
Number of subjects: 20
Study 27677161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet (0.00165%, BID)
Number of subjects: 221
Study 27677161 — intervention group
Group type: COMPARATOR
Intervention: Nystatin oral suspension (500,000 units, QID)
Number of subjects: 221
Study 27677161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet
Number of subjects: 221
Study 27677161 — intervention group
Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 221
Study 26267732 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution 10%
Number of subjects: 0
Study 26267732 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 23349532 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed emptying (after insertion; n=100)
Number of subjects: 200
Study 23349532 — intervention group
Group type: COMPARATOR
Intervention: Immediate emptying (before insertion; n=100)
Number of subjects: 200
Study 21311899 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 4570
Study 21311899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (in statin group)
Number of subjects: 4570
Study 21311899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (in non-statin group)
Number of subjects: 4570
Study 21311899 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 4570
Study 19646801 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (10-month supervised program, 3 times weekly)
Number of subjects: 59
Study 18298872 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of levobupivacaine and clonidine
Number of subjects: 60
Study 18298872 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus infusion of levobupivacaine and clonidine
Number of subjects: 60
Study 15572990 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A injection + physiotherapy rehabilitation program
Number of subjects: 40
Study 15572990 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy rehabilitation program only
Number of subjects: 40
Study 12847735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and oral L-phenylalanine (100 mg/Kg/day and gel at 10%) with 0.025% clobetasol propionate at night, sunlight or UVA exposure
Number of subjects: 70
Study 9240190 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial radiofrequency therapy (IRFT)
Number of subjects: 50
Study 9240190 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 50
Study 8494011 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted protein diet
Number of subjects: 456
Study 8494011 — intervention group
Group type: COMPARATOR
Intervention: Controlled protein diet
Number of subjects: 456
Study 8494011 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 456
Study 8494011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast progressive CRI
Number of subjects: 456
Study 8494011 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly progressive CRI
Number of subjects: 456
Study 3815009 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol, 350 mg I/ml (Omnipaque, Nycomed UK Ltd)
Number of subjects: 62
Study 3815009 — intervention group
Group type: COMPARATOR
Intervention: iopamidol, 370 mg I/ml (Niopam, E. Merck Ltd)
Number of subjects: 62
Study 11293560 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 100
Study 11293560 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 100
Study 31393518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy (at least 2 years, with an option for 3 additional years for those without recurrence)
Number of subjects: 462
Study 31393518 — intervention group
Group type: COMPARATOR
Intervention: No endocrine therapy (control group)
Number of subjects: 462
Study 30345969 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 percent silver diamine fluoride (SDF)
Number of subjects: 40
Study 30345969 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (Control)
Number of subjects: 40
Study 27902588 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-oriented hypertension management
Number of subjects: 6000
Study 27902588 — intervention group
Group type: COMPARATOR
Intervention: Normally therapy method (Control)
Number of subjects: 6000
Study 25262111 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume measurement
Number of subjects: 92
Study 25262111 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT volume as a predictor
Number of subjects: 92
Study 22483180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerne cast
Number of subjects: 66
Study 22483180 — intervention group
Group type: COMPARATOR
Intervention: Forearm cast
Number of subjects: 66
Study 19962164 — intervention group
Group type: EXPERIMENTAL
Intervention: LVA
Number of subjects: 66
Study 19962164 — intervention group
Group type: COMPARATOR
Intervention: CPB
Number of subjects: 66
Study 18182463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (3 microg/kg/min for 6 hours)
Number of subjects: 19
Study 18182463 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 19
Study 18182463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 19
Study 16265968 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 6092
Study 16265968 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 6092
Study 12028325 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 2392
Study 12028325 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2392
Study 12028325 — intervention group
Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 2392
Study 10626698 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator Methods' relative leg-length evaluation
Number of subjects: 34
Study 7797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest left ventricular ejection fraction
Number of subjects: 0
Study 7797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise ejection fraction
Number of subjects: 0
Study 7797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ejection fraction from rest to exercise
Number of subjects: 0
Study 7797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients unable to exercise or those not having a rest study
Number of subjects: 0
Study 7797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with Multicenter Postinfarction Research Group data
Number of subjects: 0
Study 2109197 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg per day)
Number of subjects: 66
Study 2109197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2109197 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 66
Study 6989681 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephabol (pyritinol)
Number of subjects: 0
Study 6989681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30265560 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Immunoglobulin G-Based Elimination Diet
Number of subjects: 0
Study 30265560 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (Control)
Number of subjects: 0
Study 28556498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (measured by urinary sodium concentration)
Number of subjects: 465
Study 25943661 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated-not thirsty (EU-NT)
Number of subjects: 11
Study 25943661 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated-thirsty (EU-T)
Number of subjects: 11
Study 25943661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated-not thirsty (DH-NT)
Number of subjects: 11
Study 25943661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated-thirsty (DH-T)
Number of subjects: 11
Study 25943661 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst condition (T)
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated (EU)
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Dehydrated (DH)
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Not thirsty (NT)
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Thirsty (T)
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Completion time
Number of subjects: 11
Study 25943661 — intervention group
Group type: COMPARATOR
Intervention: Pacing profile
Number of subjects: 11
Study 24439929 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 364
Study 24439929 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on day 1 and day 8) plus Cisplatin (75 mg/m² on day 1)
Number of subjects: 364
Study 24439929 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 364
Study 24439929 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin
Number of subjects: 364
Study 22959989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(3) pfu
Number of subjects: 479
Study 22959989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(4) pfu
Number of subjects: 479
Study 22959989 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 4 × 10(5) pfu
Number of subjects: 479
Study 22959989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study 19576944 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV‐23 (given 8 weeks after PCV‐7)
Number of subjects: 70
Study 19576944 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV‐23 (given 10 months after PCV‐7)
Number of subjects: 70
Study 19576944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pneumococcal immunization
Number of subjects: 70
Study 19576944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequential pneumococcal vaccine regimens
Number of subjects: 70
Study 17576388 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN
Number of subjects: 38
Study 17576388 — intervention group
Group type: COMPARATOR
Intervention: standard IFN
Number of subjects: 38
Study 15903358 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training
Number of subjects: 45
Study 15903358 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserve training
Number of subjects: 45
Study 15903358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 11262514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 135
Study 11262514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and nonexposure-based behavior therapy
Number of subjects: 135
Study 9555821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel and cream containing polyolprepolymer‐2
Number of subjects: 0
Study 9555821 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream containing polyolprepolymer‐2
Number of subjects: 0
Study 9555821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel containing polyolprepolymer‐2 and three tretinoin prototype creams containing polyolprepolymer‐2
Number of subjects: 0
Study 9555821 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin gel formulation containing polyolprepolymer‐2
Number of subjects: 0
Study 7930484 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 plasma levels
Number of subjects: 57
Study 7930484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha plasma levels
Number of subjects: 57
Study 7930484 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 57
Study 3063051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointments containing nystatin and/or fusidic acid
Number of subjects: 50
Study 3063051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 50
Study 3063051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31764962 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 62
Study 31764962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31553661 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiation Therapy (WBRT)
Number of subjects: 215
Study 31553661 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 215